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ECONOMIC EVALUATION OF LONG-ACTING INSULIN ANALOGUES
FOR THE TREATMENT OF PATIENTS WITH TYPE-1 AND TYPE-2
DIABETES MELLITUS IN CANADA
Belanger D, Cameron CG
Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada
OBJECTIVES: To estimate the cost-effectiveness of using long-acting insulin analogues 
(LAIAs) compared to neutral protamine hagedorn (insulin NPH), in the treatment of 
diabetes mellitus (DM). This information may assist policy makers in making informed 
decisions on reimbursement of LAIAs. METHODS: An economic evaluation, from 
the perspective of a third-party provincial payer, was conducted using the Center
for Outcomes Research (CORE) Diabetes Model (CDM). Clinical outcomes (e.g., 
A1c and hypoglycaemia) were derived from recent meta-analyses. Costs and utilities,
both discounted at 5%, were obtained from published sources. Sensitivity analyses 
were performed to test the robustness of results. RESULTS: Type-1 DM (T1DM) – 
the incremental cost-utility ratio (ICUR) for insulin glargine relative to insulin NPH, 
was $87,932 per Quality Adjusted Life Year (QALY) gained (difference ($) in cost,
$3423; $QALYs, 0.039). The ICUR for insulin detemir relative to insulin NPH, was
$387,729 per QALY gained ($cost, $4,344; $QALYs, 0.011). Type-2 DM (T2DM) – 
the ICUR for insulin glargine relative to insulin NPH, was $642,994 per QALY gained
($cost, $4,945; $QALYs, 0.008). Insulin detemir was more costly ($6,521 per patient) 
and less effective (0.034 QALYs) than insulin NPH. Results were sensitive to 
variations of parameters in sensitivity analyses. CONCLUSIONS: Compared with 
insulin NPH, the use of LAIAs for the treatment of DM was associated with relatively 
high ICURs.
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ECONOMIC EVALUATION OF METFORMIN, METFORMIN + SIBUTRAMIN 
OR ACARBOSE IN THE MANAGEMENT OF OVERWEIGHT AND OBESE
DIABETES PATIENTS
Salinas Escudero G1, Idrovo J2, Zapata L2
1Hospital Infantil de México Federico Gómez, México DF, Distrito Federal, Mexico, 2Guia
Mark, Mexico, DF, Mexico
OBJECTIVES: Diabetes mellitus is an important public health problem in Mexico.
The illness progression is faster when the patient also presents overweight or obesity. 
The objective of this study was to evaluate the clinical and economical impact of the 
use of metformine  sibutramine versus metformine and acarbose as a treatment for 
weight loss in patients with DM-2 with obesity and/or overweight, in Mexico. 
METHODS: Cost-effectiveness analysis by decision tree of the pharmacological treat-
ments for weight loss in patients with diabetes mellitus II from the health service pro-
vider perspective, considering a temporary horizon of 5 years. The considered 
effectiveness measure was the percentage of patients that reaches an IMC a 25 without 
peritoneal dialysis. Costs were estimated using 2008 prices and are expressed in US
dollars (exchange rate of 11.14 pesos/ 1 US dollar). RESULTS: According to the 
model, the effectiveness of each alternative was: metformine, 2.16%; acarbose, 2.16%
and metformine  sibutramine 50.18%. The treatement with metformine threw the 
lowest average cost per treated patient with DM-2 $9,486.3, followed by the treat-
ments with metformine  sibutramine y acarbose with a cost of $10,729.3 y $10,892.0 
respectively. The average treatment cost-effectiveness in ascending order is: met-
formine  sibutramine $21,383.5, metformine $438,183.3; and acarbose $503,116.7. 
The incremental cost of metformine  sibutramine is $2589.1 and acarbose is an 
alternative dominated by metformine. CONCLUSIONS: Metformine  sibutramine is 
a cost-effective alternative from the institutional perspective, in order to accomplish 
the weight loss in patients with diabetes mellitus type 2, with obesity or overweight 
in Mexico.
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COMPARISON OF GLUCOMETERS USED FOR SELF-MONITORING 
BLOOD GLUCOSE AMONG DIABETIC PATIENTS: A COST
MINIMIZATION APPROACH.
Goyal R, Sansgiry SS
University of Houston, Houston, TX, USA
OBJECTIVES: The purpose of this study was to compare glucometers used for self-
monitoring blood glucose in diabetic patients available at pharmacy stores by conduct-
ing a cost minimization analysis. METHODS: A prospective cross-sectional study 
design was used. Data was collected from 28 pharmacies, 4 each from local chain
pharmacies namely CVS, Walgreens, Wal-Mart, Kroger, Randall’s (Safeway), Target, 
and HEB in the Houston area. Glucometer use resource cost was calculated from
patient’s perspective and included the price of glucometers, lancet, and strips from
each pharmacy store. The annual effective cost for glucometer use was calculated by
considering number of tests performed by patients per day multiplied by the resource 
cost. A literature search from January 1996 to February 2007 was used to obtain uti-
lization patterns for patients with type 1 and type 2 diabetes (T1D andT2D, respec-
tively). Data was entered in an excel sheet and a cost minimization analysis was
performed. RESULTS: Only 4 generic glucometers were identiﬁ ed in the 28 pharma-
cies, while there were 10 branded glucometers in each. The price of glucometers,
lancets, and strips differed by location and brand. HEB store brand glucometer, In
ControlTM, was the most cost effective generic glucometer (annual cost, T1D $500.9,
T2D $172.2). By selecting the appropriate generic glucometer, patients could save 
annually $125.9 to $148.94 (T1D patients) and $15.25 to $54.4 (T2D patients),
respectively. The most cost effective brand name glucometer was by FreestyleTM 
obtained at Wal-Mart stores (annual cost, T1D $823.7, T2D $307.1). Depending upon 
the appropriately selected brand name glucometer, patients could save annually $168.3 
to $627.6 (T1D patients) and $61.0 to $226.6 (T2D patients), respectively. CONCLU-
SIONS: The cost to use glucometers varied by location and brand selected. Patients
could save cost associated with testing their blood glucose by selecting the right glu-
cometer that ﬁ ts their budget.
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USE OF GENERALIZED LINEAR MODEL TO FIND THE RELATIONSHIP
BETWEEN DIAGNOSIS AND THE COST OF DIABETIC OUTPATIENTS
Wang X
University of Louisville, Louisville, KY, USA
OBJECTIVES: The purpose of this paper is to evaluate the relationship between the 
patient diagnoses and the Claims for total charges for outpatients with diabetes. We
examine treatments in relationship to costs. METHODS: The dataset ‘Outpatient-
base-claim’of size 2,030,078 used for this paper is taken from the Chronic Condition 
Data Warehouse, which contains claim information for the year 2004. In this study, 
we use Summary Statistics, One-Way Frequencies, the Generalized Linear model in
SAS Enterprise Guide 4.1 and Kernel Density Estimation. We utilize Filter and Query,
Append Table, Join Table as well as Random Sampling to preprocess the data in order 
to analyze it. Although this dataset contains ICD9 codes for both diagnosis and pro-
cedures, Deductible and Coinsurance and so on, we mainly concentrate on patient
diagnosis information and total charges. One-way frequency counts gave us the top 
20 reasons for total charges and we use these 20 diagnoses to deﬁ ne 0–1 indicator 
functions for regression. RESULTS: The results of the Summary Statistics show that
the total charges for diagnosis are reduced considerably for payment. Kernel Density 
Estimation shows that the distribution of the total charges follows a Gamma distribu-
tion and most of the charges are under 3500 dollars. The Generalized Linear Model 
shows that only 15 of the newly-generated factors are signiﬁ cant to the model, and
these include Type II diabetes mellitus and chronic kidney disease. Renal failure is the 
most expensive condition to treat. CONCLUSIONS: Diagnosis has an important effect
on the total charges of diabetic patients, but only 15 out of 20 diseases such as
unspeciﬁ ed essential hypertension and chronic kidney disease are statistically signiﬁ -
cant to the total charges. Chronic kidney disease has the most important effect on the
total charges.
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RACE AND GENDER DIFFERENCES IN ECONOMIC BURDEN OF 
DIABETES HOSPITALIZATIONS IN TENNESSEE
White-Means S, Franklin BE, Brown LT
University of Tennessee Health Science Center, Memphis, TN, USA
OBJECTIVES: Tennessee residents face a heavy economic burden of diabetes. Costs 
of hospitalization and treatment were $2.9 billion in 2003. This study expands on 
previous work, analyzing race and gender differences in inpatient and outpatient hos-
pital costs for patients with a primary diagnosis of diabetes in Tennessee. We hypoth-
esize that Non-Hispanic Blacks, especially men, bear a disproportionately higher 
burden compared to Non-Hispanic Whites. METHODS: This study utilized inpatient
and outpatient ﬁ les from the 2003 Tennessee Hospital Discharge Data System. Chi-
square and t-tests were performed to analyze signiﬁ cant differences in key demo-
graphic and clinical factors among race-gender groups. Multivariate regression models
were developed to estimate log inpatient and outpatient charges for all hospitalizations 
with a primary diagnosis of diabetes (ICD-9 code: 250). RESULTS: Analyses revealed 
signiﬁ cant differences in comorbid presentations across race-gender groups and other 
factors contributing to charges. Overall, women were signiﬁ cantly more likely to
present with hypertension than men, although percentages for blacks were signiﬁ cantly 
higher (all p  0.001). Ulcers were more prevalent in men versus women (all p  0.001), 
highest among white men (signiﬁ cant only for outpatient events, p  0.001), and 
resulted in signiﬁ cantly higher (48%, p  0.0001) inpatient charges. As predicted, 
hospital charges were highest among blacks, although black males had signiﬁ cantly 
higher (20.2%, p  0.0001) mean inpatient charges and black females had signiﬁ cantly
higher (6.8%, p  0.0001) outpatient charges. CONCLUSIONS: To improve the 
quality of care in diabetes, it is critical to identify disparities in treatment. The analysis
revealed that a signiﬁ cantly higher percentage of men suffered ulcers, which signiﬁ -
cantly increased inpatient charges. As such, gender-targeted education may be war-
ranted to reduce the incidence of diabetic ulcers. In addition, increased prevention 
efforts may be necessary in black communities to reduce avoidable hospitalizations.
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DIRECT COST OF DIABETES IN OPD CLINICS OF PAKISTAN
Khowaja LA, Khuwaja AK
Aga Khan University, Karachi, Sindh, Pakistan
OBJECTIVES: Diabetes is a chronic and potentially disabling disease that represents
an important public health and clinical concern. It is a growing epidemic and the cost 
of treating diabetes is largely increasing. This is ﬁ rst of its kind of research study con-
ducted in Pakistan. This study aimed to estimate the direct cost of Diabetes at out-
patient clinics in Karachi, Pakistan, and to identify the high cost component of diabetes 
care. METHODS: Prevalence based Cost of Illness study was conducted in different 
out-patient clinics representing public, private and NGO/trustee based hospitals of 
Karachi, Pakistan in 2006. After taking informed consent, a pre-tested questionnaire 
was used to collect the data from 345 randomly selected persons with diabetes. 
RESULTS: The only annual mean direct cost tolerated by each person with diabetes 
was estimated to Pakistani rupees 11,580 (US$ 193). We found that increasing age, 
number of complications and longer duration of disease signiﬁ cantly increases the
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burden of cost on society (p  0.001). The largest portion of direct cost was devoted 
to medicines (46%) followed by laboratory investigations (32%). Comparing cost 
with family income, we also found that poorest segment of society is spending about 
18% of total family income on diabetes care. CONCLUSIONS: The overwhelming
cost threatens to stunt economic growth and undermines the living standard. The 
overall cost can be abridged by prevention of diabetes, earlier detection of disease and 
improved diabetes care. Prevention programs need to be initiated at lager scale to
enhance health gain to the individual and to reverse the advance of this epidemic. 
Policy makers need to ascertain the priority of diabetes education and prevention 
programs at primary health care outlets as an integral component.
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EXCESS COSTS OF DIABETES MELLITUS AMONG MEDICARE
RECIPIENTS IN A SKILLED NURSING FACILITY SETTING
Boulanger L1, Kongsø JH2, Bouchard JR3, Christensen T4, Fraser K1, Russell MW1
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Novo Nordisk A/S, Bagsvaerd, 
Denmark, 3Novo Nordisk, Inc., Princeton, NJ, USA, 4Novo Nordisk A/S, Bagsværd, Denmark
OBJECTIVES: This retrospective matched cohort study compared resource utilization
and costs between diabetic and non-diabetic patients requiring skilled nursing facility
(SNF) admissions. METHODS: Patients with a SNF admission for at least 30 days 
during 2004 were identiﬁ ed from a 5% random sample of Medicare patients. The 
“diabetes” cohort consisted of patient with an ICD-9-CM diagnosis on 1 SNF claims. 
Each diabetes patient was matched (by age, sex, and race) with one patient having no
diabetes claims in 2004 and followed for 12 months. The diabetes and non-diabetes
cohorts were compared, both overall and within subgroups deﬁ ned by age, with 
respect to rates of diabetes complications/conditions and co-morbid conditions, health
care resource utilization, and Medicare payments in 2005. Ordinary least squares 
regression was used to estimate adjusted costs controlling for comorbid conditions
(i.e., selected chronic conditions, Charlson comorbidity score). RESULTS: We identi-
ﬁ ed 20,477 diabetic patients and 78,154 non-diabetic patients in 2004. Following
matching, there were 20,158 in each group (45% aged 80 years, 62% female, 82%
white). Relative to matched controls, diabetic patients had higher Charlson comorbid-
ity scores and were more likely to have complications such as congestive heart failure 
(24.1% vs. 18.1%, p  0.01) and renal disease (11.2% vs. 6.7%, p  0.01). On
average, diabetic patients had an additional one-half day (p  0.01) in the hospital 
over one year of follow-up. Total unadjusted mean Medicare payments were greater 
among diabetic patients than controls ($26,075 vs. $24,622, p  0.01), primarily due
to differences in inpatient costs. After adjusting for comorbidities, total costs were 
$969 higher among diabetic patients (p  0.01). Excess costs were greater among 
patients 70 years ($1269, p  0.01) versus those 70 years ($892, p  0.01). CON-
CLUSIONS: These ﬁ ndings suggest that diabetic patients in skilled nursing facilities
had higher health care costs than non-diabetic patients even after controlling for
complications related to diabetes and chronic comorbidity.
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IMPROVEMENT IN CARDIOVASCULAR RISK FACTORS AND LONG-TERM
OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES TREATED WITH
LIRAGLUTIDE OR GLIMEPIRIDE MONOTHERAPY
Alfonso R1, Sullivan SD1, Conner C2, Hammer M3, Blonde L4
1University of Washington, Seattle, WA, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA, 3Novo
Nordisk A/S, Bagsværd, Denmark, 4Ochsner Medical Center, New Orleans, LA, USA
OBJECTIVES: Morbidity, mortality, and costs of Type 2 Diabetes (T2D) remain high 
despite the available efﬁ cacious treatment options. New agents have shown improve-
ments in A1C and other surrogates but long-term impacts are unknown. METHODS:
Data from randomized controlled trial of liraglutide monotherapy (LEAD 3) was used 
to determine long-term consequences of treatment with liraglutide, a new OD GLP-1 
analog, compared to glimepiride in a simulated 30-year follow-up. The CORE diabetes 
model, calibrated to LEAD 3 baseline patient characteristics, employed data from 
long-term studies to project morbidity, mortality and costs of T2D. We simulated
clinical and economic consequences of patients receiving liraglutide 1.2mg and 1.8mg
compared to glimepiride 8 mg, all as monotherapy, for treatment of T2D. The effect
of treatment on A1C, SBP, lipids, weight and risk of hypoglycemia was taken into
account. Survival, cumulative incidence of CV, ocular, renal events and costs (dis-
counted 3%/yr) were estimated over three periods: 10, 20, 30 years. RESULTS: Simu-
lations produced higher survival rates for liraglutide 1.8 mg and 1.2 mg compared to
glimepiride after 30 years’ follow-up (16.5%, 13.6%, 7.3%, respectively). Highest
difference in fatal events across treatment groups related to end-stage renal disease, 
although the main cause of death in all groups was associated with CV events. Non-
fatal renal and ocular events were lower for both liraglutide doses. Neuropathies that
led to a ﬁ rst or recurrent amputation were higher for glimepiride compared to the 
liraglutide doses. The average cumulative cost per patient was US$9367 higher for
glimepiride at year 30, compared to liraglutide 1.8mg, and US$6491 higher than 
liraglutide 1.2 mg. CONCLUSIONS: The main cost component for all groups was
management of CV events. Using the CORE model and data from LEAD 3, projected
survival, diabetes complications and costs over the long term favored liraglutide 
1.2 mg and 1.8 mg compared to glimepiride in the treatment of T2D.
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LONG-TERM OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES
RECEIVING GLIMEPIRIDE COMBINED WITH LIRAGLUTIDE OR
ROSIGLITAZONE
Alfonso R1, Sullivan SD1, Conner C2, Hammer M3, Blonde L4
1University of Washington, Seattle, WA, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA, 3Novo 
Nordisk A/S, Bagsværd, Denmark, 4Ochsner Medical Center, New Orleans, LA, USA
OBJECTIVES: Poor control of type 2 diabetes (T2D) results in substantial morbidity
and economic burden to the health care system. Studies of new T2D treatments are
rarely designed to assess mortality, complication rates and costs. We sought to estimate 
long-term consequences of liraglutide and rosiglitazone both as add-on to glimepiride. 
METHODS: To estimate clinical and economic consequences, we used the CORE 
diabetes model, a validated cohort model that uses data from long-term clinical trials
to simulate morbidity, mortality and costs of T2D. Clinical data were extracted from 
the randomized double-blinded placebo-controlled LEAD 1 trial evaluating two doses 
(1.2 mg and 1.8 mg) of a once daily human GLP-1 analog liraglutide, or rosiglitazone
4 mg, added to glimepiride. The CORE diabetes model was calibrated to the LEAD 1
baseline patient characteristics. Survival, cumulative incidence of cardiovascular, ocular 
and renal events and costs were estimated over three periods: 10, 20 and 30 years.
RESULTS: In a cohort of 5000 patients per treatment followed for 30 years, liraglutide 
1. mg and 1.8 mg had higher survival compared to the group treated with rosiglitazone 
(15.0% and 16.0% vs. 12.6% after 30 years), and fewer cardiovascular, renal, and
ocular events. Cardiovascular deaths after 30 years were 69.7%, 68.4% and 72.5%,
for liraglutide 1.2 mg, 1.8 mg, and rosiglitazone, respectively. First and recurrent 
amputations were lower in the rosiglitazone group compared to both doses of liraglu-
tide (number of events: 565, 529 and 507 for liraglutide 1.2 mg, 1.8 mg, and rosigli-
tazone, respectively). CONCLUSIONS: Overall cumulative costs per patient were 
lower in both liraglutide groups compared to rosiglitazone mainly driven by the costs
of cardiovascular events (US$38,963, $39,239, and $40,401 for liraglutide 1.2 mg, 
1.8 mg, and rosiglitazone, respectively). Projected survival and long term outcomes 
favored liraglutide 1.2 mg and 1.8 mg over rosiglitazone both added to glimepiride.
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CHANGES IN OPIOID USE AND ECONOMIC OUTCOMES AMONG
DIABETIC PERIPHERAL NEUROPATHIC PAIN PATIENTS TREATED WITH
DULOXETINE
Boulanger L1, Wu N1, Chen SY1, Fraser K1, Zhao Y2
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, 
USA
OBJECTIVES: Among patients diagnosed with diabetic peripheral neuropathic pain 
(DPNP); whether adherence to duloxetine therapy was correlated with opioid medica-
tion use and health care expenditures. METHODS: Diabetic patients who were dis-
pensed duloxetine between March 1, 2005 and December 31, 2005 were identiﬁ ed 
from a large administrative claims database and an “index date” was assigned based
on the dispense date of the ﬁ rst duloxetine claim. Included patients were 18 to 64 
years old, diagnosed with DPNP in the one year prior to the index date, and received 
opioids in the prior 90 days. Adherence to duloxetine therapy was based on medica-
tion possession ratio (MPR), and patients were dichotomized as “continuous” (MPR
q 0.8) and “non-continuous” (MPR  0.8) users. We examined changes in short-acting 
(SA) and long-acting (LA) opioid utilization one year before and after the index date. 
One year health care utilization and costs were also examined. Multivariate linear 
regressions were performed to examine the association between duloxetine adherence 
and study outcomes, controlling for baseline demographic and clinical characteristics.
RESULTS: We identiﬁ ed 97 continuous users and 245 non-continuous users of dulox-
etine. Compared with non-continuous patients, continuous users had a greater reduc-
tion in days on SA hydrocodone (30.2, p  0.05), number of SA hydrocodone 
prescriptions (1.7, p  0.05), and days on DPNP-related SA opioids (23.8, p  0.05). 
We did not observe any signiﬁ cant reduction in LA opioid use. Continuous users also
had 40% fewer inpatient stays (p  0.05) and fewer days in hospital (3.5, p  0.05). 
In the regression model, we found continuous users had $17,062 less (p  0.05) total 
health care cost than non-continuous users mainly attributable to lower inpatient costs 
($16,932, p  0.05). The outpatient and pharmacy costs were similar between cohorts.
CONCLUSIONS: Continuous duloxetine users were more likely to have a reduction
in SA opioids use and have lower hospital expenditures than non-continuous dulox-
etine users.
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DAILY AVERAGE CONSUMPTION OF BASAL INSULIN IN
PATIENTS WITH TYPE 2 DIABETES
McAdam-Marx C1, Yu J1, Shankar V2, Bouchard JR3, Brixner D1
1University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2SDI, Plymouth Meeting, 
PA, USA, 3Novo Nordisk, Inc., Princeton, NJ, USA
OBJECTIVES: study compared the daily average consumption (DACON) of insulin 
detemir (DET), insulin glargine (GLAR) and NPH insulin in patients with T2D in a
real-world setting. METHODS: Patients with T2D (per ICD-9 code 250.x1 250.x3)
newly treated with DET, GLAR or NPH insulin monotherapy were identiﬁ ed in the 
Verispan Electronic Data Warehouse (SDI, Plymouth Meeting, PA) from 7/1/2006 to 
6/31/2007. A study limitation is that Verispan data has an open architecture and does
not include eligibility data, but ﬁ ltering techniques were employed to eliminate cohort 
shrinkage. A patient level DACON was calculated as the number of insulin units dis-
pensed from the ﬁ rst to the second to last prescription in the observation period 
divided by the elapsed days from the ﬁ rst to last ﬁ ll. Unpaired t-tests and chi-square 
